DENVER, CO / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the...
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
DENVER, CO / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at...
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
DENVER, CO / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter,...
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
DENVER, CO / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted...
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx SegmentEliminates Materially All Remaining Expenses Associated with the Consumer Health BusinessProvides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / August 6,...
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debtInterest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life...
Aytu BioPharma (AYTU) Fireside Chat
In this discussion, we welcome Aytu BioPharma, NASDAQ ticker symbol AYTU. And with us today is their Chief Executive Officer, Josh Disbrow. Aytu is a pharmaceutical company focused on commercializing novel therapeutics. This Fireside Chat was recorded during the...
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
DENVER, CO / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one...
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4...
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
DENVER, CO / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended...